Uk Advisory Council On The Misuse Of Drugs

Government Response to ACMD 3 Medicines Reports on Drug Scheduling

The UK government agrees with ACMD recommendations to control three growth hormones (somapacitan, lonapegsomatropin, somatrogon) under Class C of the Misuse of Drugs Act 1971 and Schedule 4 (Part 2) of the Misuse of Drugs Regulations 2001. Ganaxolone will not be scheduled at this time. Zuranolone will be controlled under Class C and Schedule 4 (Part I) for treatment of post-natal depression.

Letter on ACMD Work Programme 2026

The Advisory Council on the Misuse of Drugs (ACMD) published its work programme for 2026, outlining planned advisory activities and ongoing ministerial commissions. The letter from the ACMD Chair to the Minister for Policing and Crime details both requested advice and self-initiated work the council will undertake during the year.

Register of ACMD Members' Interests and Occupations

The Advisory Council on the Misuse of Drugs (ACMD) maintains a register of interests for its council members, listing their occupations, employing organisations, and declared interests. The document was updated on 23 March 2026 to add a new trustee position for Roger Knaggs and on 17 March 2026 to update Professor Keith Humphreys' interests. Two new members, Professor Steve Allsop and Professor Keith Humphreys, were added with their declarations of interests on 2 February 2026. The register is an administrative transparency document for UK government advisory council members.

Professor Allsop, Professor Humphreys Join ACMD

The Advisory Council on the Misuse of Drugs (ACMD) has appointed Professor Steve Allsop and Professor Keith Humphreys as new members effective 1 February 2026. Professor Allsop is Emeritus Professor at the National Drug Research Institute, Curtin University, Australia. Professor Humphreys is the Esther Ting Memorial Professor in the Department of Psychiatry and Behavioural Sciences at Stanford University. These appointments follow 14 other experts joining the ACMD in 2025.

Ethylbromazolam Review Recommends Class C Control Under Misuse of Drugs Act 1971

The Advisory Council on the Misuse of Drugs published a review on 14 April 2026 recommending that the novel benzodiazepine ethylbromazolam be made a Class C drug under the Misuse of Drugs Act 1971 and added to Schedule 1 of the Misuse of Drugs Regulations 2001. The recommendation is based on evidence of misuse and harms associated with the substance.